<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320859">
  <stage>Registered</stage>
  <submitdate>23/11/2009</submitdate>
  <approvaldate>24/11/2009</approvaldate>
  <actrnumber>ACTRN12609001020279</actrnumber>
  <trial_identification>
    <studytitle>The Exelon Patch (Transdermal Rivastigmine) for the treatment of severe delirium in elderly subacute care inpatients</studytitle>
    <scientifictitle>A double blinded randomised placebo controlled trial of the exelon patch (transdermal rivastigmine) for the treatment of severe delirium in elderly subacute care inpatients.</scientifictitle>
    <utrn>U1111-1112-5952</utrn>
    <trialacronym>EPFD1</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Delirium in elderly subacute care inpatients</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Transdermal Rivastigmine 4.6mg/hour patch applied topically changed daily for two weeks.</interventions>
    <comparator>Placebo; Placebo patch identical in  appearance to the Transdermal Rivastigmine, without the active ingredient, applied topically and changed daily for two weeks.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Peak Delirium Severity on Delirium Rating Scale.</outcome>
      <timepoint>week two of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>nil</outcome>
      <timepoint>nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Severe Delirium (Confusion assessment method positive, delirium rating scale 12 or more)</inclusivecriteria>
    <inclusiveminage>65</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Informed consent unable to be obtained
Deficits in cardiac conducting system, resting pulse &lt;50, intolerance or allergy to rivastigmine, carbamates or excipients.
Severe dysphasia, visual or hearing impairment, or non english speaking such that unable to complete scales.
Expected prognosis or discharge less than 2 weeks.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence>permuted block randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>7/02/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3050</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Melbourne Health</primarysponsorname>
    <primarysponsoraddress>Grattan street
THE ROYAL MELBOURNE HOSPITAL
VIC 3050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Novartis Pharmaceutical Australia Pty Ltd</fundingname>
      <fundingaddress>54 Waterloo Road North Ryde  NSW 2113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Acetylcholine levels are decreased in delirium, a condition of a sudden change in mental capacity occurring due to a illness, medication or similar insult. Rivastigmine is a medication for Alzhiemer's Disease, another condition where there is a change in mental capacity and low levels of acetylcholine. It increases levels of acetylcholine in the brain. THis trial aims to determine if a rivastigmine patch given to elderly patients in hospital after their illness has resolved but who still have delirium will have a less severe delirium.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Melbourne Health Human Research and Ethics Committee.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>2009.147</hrec>
      <ethicsubmitdate>19/09/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Peter Lange</name>
      <address>National Ageing Research Institute
PO Box 2127, Royal Melbourne Hospital,
Carlton, Victoria 3050</address>
      <phone>+61 3 93427000</phone>
      <fax />
      <email>peter.lange@mh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Peter Lange</name>
      <address>National Ageing Research Institute
PO Box 2127, Royal Melbourne Hospital,
Carlton, Victoria 3050</address>
      <phone>+61 3 9342 7000</phone>
      <fax />
      <email>peter.lange@mh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Peter Lange</name>
      <address>National Ageing Research Institute
PO Box 2127, Royal Melbourne Hospital,
Carlton, Victoria 3050</address>
      <phone>+61 3 93427000</phone>
      <fax />
      <email>peter.lange@mh.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Peter Lange</name>
      <address>c/o APU Ground Floor the Royal Melbourne Hospital Grattan Street THE ROYAL MELBOURNE HOSPITAL VIC 3050 Australia</address>
      <phone>+61039342835</phone>
      <fax />
      <email>peter.lange@mh.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>